News and Announcements
Sementis Ltd – CEO Interview
- Published November 13, 2014 11:53AM UTC
- Publisher Wholesale Investor
- Categories Executive Interviews
Sementis is a biotech company developing vaccines for peanut allergy and chikungunya (like dengue fever, a mosquito-borne disease spreading throughout the world). There is an early stage pipeline for vaccines for Ebola, Q Fever, Melanoma (skin Cancer) and prostate Cancer.
The vaccines use Sementis’ “SCV” backbone technology. This is a vaccinia virus (which is also a smallpox vaccine) genetically altered to prevent replication in human cells thus ensuring safety and, through further manipulation, able to increase its immune stimulating properties. The genes for antigens from diseases are added to the SCV, which, with vaccination, elicits an immune response to the disease state in the human body.
Sementis’ Non-executive Chairman, Maurice O’Shannassy spent 25 years in the financial services industry in Australia, the United Kingdom and Asia. His most recent role was that of CEO of BlackRock Investment Management in Australia. Prior to that he was the CEO and CIO of the Asian operations of BlackRock’s antecedents, Merrill Lynch Investment Management and Mercury Asset Management.
Please listen to Sementis’ Non-executive Chairman, Mr. Maurice O’Shannassy.
Executive Interviews
Bridging the Gap: Why Australian Capital is Crucial for India’s Trillion-Dollar Growth Story
Australia’s substantial savings pool is meeting India’s explosive growth. Learn how Creek Partners is building the crucial bridge for investors seeking to tap into India’s projected $7 trillion economy and its vibrant venture capital ecosystem.
Beyond the Hype: Strategic Digital Asset Investing for a New Financial Era
The financial world is undergoing a profound transformation driven by Digital Assets. Learn why hundreds of billions are pouring into new digital infrastructure, with stablecoins now outperforming Mastercard/Visa in transaction volume. This article guides investors beyond the hype to strategic digital asset investing, exploring yield, DePIN, DeFi, and AI+Blockchain for the new financial era. Discover more at Venture & Capital SYDNEY 2025.
Cryptos New Frontier: Institutionalisation, Real-World Assets, and the End of Wild West Investing
The cryptocurrency landscape, once characterised by rapid cycles and speculative frenzy, is undergoing a profound transformation. As global institutions and high-net-worth individuals increasingly look to allocate capital to digital assets, the focus is shifting towards maturity, regulatory clarity, and the integration of blockchain technology with traditional finance. A recent at the Emergence Singapore 2025 panel […]
Backed By Leading Investment Groups and Family Offices
